Global  

Novartis Still a Buy Despite Controversy Over Blockbuster Drug, Jim Cramer Says

Video Credit: The Street - Duration: 02:30s - Published
Novartis Still a Buy Despite Controversy Over Blockbuster Drug, Jim Cramer Says

Novartis Still a Buy Despite Controversy Over Blockbuster Drug, Jim Cramer Says

Novartis and its CEO may have gotten a black eye amid a dust-up over tainted research, but the pharma giant is still a buy, according to Jim Cramer during his exclusive video-conference call on Wednesday, Nov.

13.

Despite the issues that have bubbled up related to its breakthrough drug for spinal muscular atrophy, Zolgensma, Novartis "has the newest pipeline with many drugs just beginning to have an impact on the company's bottom line," Cramer told members of his Action Alerts PLUS club for investors during an exclusive video-conference call.

Not that the issue with Zolgensma isn't embarrassing for Novartis.

Novartis CEO Vas Narasimhan acquired Zolgensma after buying the company that developed it, Avexis, only to have it revealed that some of the data behind the new drug had been falsified.

However, while the Food and Drug Administration has "come down hard" on Novartis as a result, the $425,000-a-year drug "has seen remarkable results," Cramer said.

Novartis' 3% dividend yield, and the fact "there is no evidence whatsoever that falsification would lead to pulling this one drug" should help Novartis restore its reputation as a new drug research powerhouse, Cramer said.

"Three months from now we will not be talking about tainted data from Novartis' new drug, we will be talking about strong revenues, and that should propel the stock higher," Cramer told club members.

Check Out All of Jim's Video-Conference Call Cramer's video-conference call was only available to Action Alerts PLUS members, but you can sign up for a free 14-day trial and watch a full replay.

Joining Action Alerts PLUS gives you access to all of Cramer's monthly private video-conference calls and provides you with a host of other benefits, including: A complete rundown of all of the stocks that the expert holds in his charitable trust; E-mail alerts that give you a chance to buy or sell any stock before Cramer make a trade for the trust; Custom research throughout the trading day from Cramer and his team of stock-market analysts.

You get to see some of the same research that Cramer and his team sees every market day as they make investment decisions.

Click here to join Action Alerts PLUS today!


You Might Like


Tweets about this


Related videos from verified sources

Jim Cramer: The One Thing That All These Mergers Have in Common [Video]

Jim Cramer: The One Thing That All These Mergers Have in Common

Jim Cramer has some thoughts on merger Monday. On Monday, there were a handful of deals announced. First, LVMH is officially buying Tiffany's for around $135 a share, which puts the deal at around..

Credit: The Street     Duration: 00:57Published
No More Tears for Johnson & Johnson? [Video]

No More Tears for Johnson & Johnson?

No more tears for Johnson & Johnson ? At least one analyst seems to think so, at least in the short run. The beleaguered drug and consumer products giant got a rare, healthy financial checkup and..

Credit: The Street     Duration: 01:53Published
Despite Recent Controversy, Twilio Remains a Good Buy, Jim Cramer says [Video]

Despite Recent Controversy, Twilio Remains a Good Buy, Jim Cramer says

Jim Cramer is sticking with fast-growing cloud services provider Twilio , arguing that a pair of high-profile mistakes have not dimmed the explosive growth potential of a tech company that has..

Credit: The Street     Duration: 03:43Published